Pioglitazone randomised Italian study on metabolic syndrome (PRISMA): Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients

S. Genovese, A. Passaro, P. Brunetti, M. Comaschi, D. Cucinotta, C. G. Egan, B. Chinea, F. Bravi, C. Di Pietro

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters. Subjects and Methods: This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA1c) levels between 6-8%, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis. Results: Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl vs 3.0 mg/dl; p

Original languageEnglish
Pages (from-to)606-616
Number of pages11
JournalJournal of Endocrinological Investigation
Volume36
Issue number8
DOIs
Publication statusPublished - Sep 2013

Fingerprint

pioglitazone
HDL Cholesterol
Type 2 Diabetes Mellitus
Metformin
Placebos
Intention to Treat Analysis
Abdominal Obesity
Dyslipidemias
Double-Blind Method
Hemoglobins
Multivariate Analysis

Keywords

  • HDL-cholesterol
  • Metabolic syndrome
  • Pioglitazone
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Pioglitazone randomised Italian study on metabolic syndrome (PRISMA) : Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients. / Genovese, S.; Passaro, A.; Brunetti, P.; Comaschi, M.; Cucinotta, D.; Egan, C. G.; Chinea, B.; Bravi, F.; Di Pietro, C.

In: Journal of Endocrinological Investigation, Vol. 36, No. 8, 09.2013, p. 606-616.

Research output: Contribution to journalArticle

Genovese, S. ; Passaro, A. ; Brunetti, P. ; Comaschi, M. ; Cucinotta, D. ; Egan, C. G. ; Chinea, B. ; Bravi, F. ; Di Pietro, C. / Pioglitazone randomised Italian study on metabolic syndrome (PRISMA) : Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients. In: Journal of Endocrinological Investigation. 2013 ; Vol. 36, No. 8. pp. 606-616.
@article{2e34d1c9f663434c9ebcda949f2ca302,
title = "Pioglitazone randomised Italian study on metabolic syndrome (PRISMA): Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients",
abstract = "Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters. Subjects and Methods: This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA1c) levels between 6-8{\%}, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis. Results: Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl vs 3.0 mg/dl; p",
keywords = "HDL-cholesterol, Metabolic syndrome, Pioglitazone, Type 2 diabetes mellitus",
author = "S. Genovese and A. Passaro and P. Brunetti and M. Comaschi and D. Cucinotta and Egan, {C. G.} and B. Chinea and F. Bravi and {Di Pietro}, C.",
year = "2013",
month = "9",
doi = "10.3275/8895",
language = "English",
volume = "36",
pages = "606--616",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "8",

}

TY - JOUR

T1 - Pioglitazone randomised Italian study on metabolic syndrome (PRISMA)

T2 - Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients

AU - Genovese, S.

AU - Passaro, A.

AU - Brunetti, P.

AU - Comaschi, M.

AU - Cucinotta, D.

AU - Egan, C. G.

AU - Chinea, B.

AU - Bravi, F.

AU - Di Pietro, C.

PY - 2013/9

Y1 - 2013/9

N2 - Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters. Subjects and Methods: This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA1c) levels between 6-8%, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis. Results: Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl vs 3.0 mg/dl; p

AB - Background: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM). Aim: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters. Subjects and Methods: This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA1c) levels between 6-8%, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis. Results: Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl vs 3.0 mg/dl; p

KW - HDL-cholesterol

KW - Metabolic syndrome

KW - Pioglitazone

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84885667434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885667434&partnerID=8YFLogxK

U2 - 10.3275/8895

DO - 10.3275/8895

M3 - Article

C2 - 23511244

AN - SCOPUS:84885667434

VL - 36

SP - 606

EP - 616

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 8

ER -